Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers.

ABSTRACT:

Purpose

Few efficient methylation markers of chemosensitivity have been discovered. The genome-wide analysis of methylation markers is needed to identify chemosensitive candidates to targeted therapy.

Methods

This study describes a two-step process to select chemosensitive candidates of methylation genes. A genome-wide screening of methylation genes was performed using a Beadarray and an in vitro chemosensitivity assay of 119 colorectal cancers (CRCs). Ten candidate genes identified during the initial screening were verified by biological utility assessment using cell viability assays of transfected CRC cells.

Results

Five methylation genes related to sensitivity to bevacizumab regimens (RASSF1, MMP25, KCNQ1, ESR1, and GALR2) or cetuximab regimens (SCL18A2, GPX7, NID2

SUBMITTER: Kim JC 

PROVIDER: S-EPMC11828263 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature